PCPM (Per Capita Per Month)
₹4.11 lakh
+₹0.49 lakh YoY
Productivity per medical representative improved from ₹3.62 lakh to ₹4.11 lakh.
CORONAREMEDIES
Other
30 Apr 2026
Corona Remedies Ltd — Q4 FY26
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges. EBITDA margin expanded 80bps to 20.9%, driven by favorable product mix and operating leverage. Domestic business grew 16.8%, while international surged 29.5%. Chronic segment now contributes 72% of revenue. Two brands crossed ₹100 Cr, and eight are in the ₹50-100 Cr club. Management guided for 15% organic revenue growth and 20%+ PAT growth in FY27, supported by new divisions (infertility, multispecialty), biosimilar launches (semaglutide), and acquisitions (Wokadin, Bayer portfolio). Key risk: potential gross margin pressure from rising API costs if geopolitical tensions persist.
Key Numbers
MR Strength
3,100
+450 YoY
Added 450 medical representatives in FY26, ending with total strength of 3,100.
Chronic Segment Revenue Share
71.9%
+?pp YoY
Chronic and sub-chronic segments now contribute 71.9% of total revenue.
Volume Growth vs IPM
3%
4.6x IPM
Volume growth of 3% was 4.6 times the IPM volume growth of 0.7%.
Management Guidance
15% organic revenue growth in FY27
Management expects to sustain 15%+ revenue growth organically for FY27.
Management guidance revenue25% revenue growth on acquired brands
Acquired brands (Wokadin, Bayer portfolio) are expected to grow at 25% in FY27.
Management guidance growth20%+ PAT growth in FY27
Management guided for 20%+ PAT growth in FY27.
Management guidance marginsHormone plant operational in Q1/Q2 FY27
The dedicated hormone manufacturing plant is expected to become operational in Q1 or Q2 of FY27.
Management guidance capexKey Risks
Gross margin pressure from rising API costs
Geopolitical tensions may increase API prices, impacting gross margins. Management noted indirect impact but expects to manage within 80% gross margin band.
medium · analyst_questionIntegration and margin dilution from Wokadin acquisition
Wokadin acquisition may cause ~400bps gross margin correction in first year due to NLEM portfolio. Management expects 25% revenue growth but margin recovery uncertain.
medium · analyst_questionExecution risk in new divisions and biosimilars
New infertility and multispecialty divisions, plus biosimilar launches, require ramp-up time. PCPM for new hires takes 3+ years to mature.
low · management_commentaryNotable Quotes
We expect to sustain 15% plus revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27.
Our revenue growth in FY26 was driven by a 3% increase in volumes significantly outpacing the IPM of 0.7% volume growth by nearly 4.6 times.
Semaglutide brings a new dimension to the diabetic market as well as obesity market and generic semaglutide market has been exciting for sure.
Frequently Asked Questions
What was Corona Remedies's revenue in Q4 FY26?
Corona Remedies reported revenue of ₹353 Cr in Q4 FY26, representing a +17.3% change compared to the same quarter last year.
What guidance did Corona Remedies management give for FY27?
15% organic revenue growth in FY27: Management expects to sustain 15%+ revenue growth organically for FY27. 25% revenue growth on acquired brands: Acquired brands (Wokadin, Bayer portfolio) are expected to grow at 25% in FY27. 20%+ PAT growth in FY27: Management guided for 20%+ PAT growth in FY27. Hormone plant operational in Q1/Q2 FY27: The dedicated hormone manufacturing plant is expected to become operational in Q1 or Q2 of FY27.
What are the key risks for Corona Remedies in FY27?
Key risks include Gross margin pressure from rising API costs — Geopolitical tensions may increase API prices, impacting gross margins. Management noted indirect impact but expects to manage within 80% gross margin band.; Integration and margin dilution from Wokadin acquisition — Wokadin acquisition may cause ~400bps gross margin correction in first year due to NLEM portfolio. Management expects 25% revenue growth but margin recovery uncertain.; Execution risk in new divisions and biosimilars — New infertility and multispecialty divisions, plus biosimilar launches, require ramp-up time. PCPM for new hires takes 3+ years to mature..
Did Corona Remedies meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Corona Remedies Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.